ASH 2010 Homepage Header

News
Article

Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.

 

  • Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy

  • Ofatumumab generates high response rates in refractory CLL

  • Industry update: Early-stage trials establish pathways for new treatment agents
     
  • More Coverage from ASH 2010
Recent Videos
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content
Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Ibrutinib/Venetoclax Yields Long-Term Efficacy in Japanese R/R MCL Trial

Russ Conroy
December 5th 2025
Article

Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Roman Fabbricatore
December 5th 2025
Article

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Tim Cortese
December 4th 2025
Article

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

Russ Conroy
December 4th 2025
Article

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.